Randomizing patients among treatments with equal probabilities in clinical trials is the established method to obtain unbiased comparisons. In recent years, motivated by ethical considerations, many authors have proposed outcome adaptive randomization, wherein the randomization probabilities are unbalanced, based on interim data, to favor treatment arms having more favorable outcomes. While there has been substantial controversy regarding the merits and flaws of adaptive versus equal randomization, there has not yet been a systematic simulation study in the multi-arm setting. A simulation study was conducted to evaluate four different Bayesian adaptive randomization methods and compare them to equal randomization in five-arm clinical trials. All adaptive randomization methods included an initial burn-in with equal randomization and some combination of other modifications to avoid extreme randomization probabilities. Trials either with or without a control arm were evaluated, using designs that may terminate arms early for futility and select one or more experimental treatments at the end. The designs were evaluated under a range of scenarios and sample sizes. For trials with a control arm and maximum same size 250 or 500, several commonly used adaptive randomization methods have very low probabilities of correctly selecting a truly superior treatment. Of those studied, the only adaptive randomization method with desirable properties has a burn-in with equal randomization and thereafter randomization probabilities restricted to the interval 0.10-0.90. Compared to equal randomization, this method has a favorable sample size imbalance but lower probability of correctly selecting a superior treatment. In multi-arm trials, compared to equal randomization, several commonly used adaptive randomization methods give much lower probabilities of selecting superior treatments. Aside from randomization method, conducting a multi-arm trial without a control arm may lead to very low probabilities of selecting any superior treatments if differences between the treatment success probabilities are small.
Introduction
Outcome adaptive randomization (AR) has been proposed by many authors as an alternative to equal randomization (ER), for comparing treatments A and B. AR uses the interim outcome data to unbalance randomization probabilities in favor of the treatment arm, or arms, having currently higher empirical success rates. Proponents of AR consider it more ethical than ER for the patients enrolled in the trial because AR leads to sample sizes, N A , and N B , on average unbalanced in favor of the truly superior treatment. AR was proposed by Thompson 1 for binary outcomes. He suggested that, assuming success probabilities p A and p B following beta priors, the nth patient should receive treatment A with probability r A, n = Pr(p B \p A j data n ) and B with probability r B, n = 1 À r A, n : Adaptive statistical criteria used to define AR probabilities similar to r A, n and r B, n sometimes are called ''randomized play-the-winner'' rules. 2, 3 Many different AR methods have been proposed, and clinical trials have been conducted using various AR methods. [4] [5] [6] [7] [8] [9] [10] Use of AR in clinical trials remains controversial. Critics argue that AR provides a small advantage in sample size imbalance in favor of the superior treatments, while introducing inferential problems that decrease benefit to future patients. Discussions of AR have been given by many authors. [11] [12] [13] [14] [15] [16] [17] [18] Berry has argued that the greatest advantages of AR over ER may be obtained in multi-arm trials. Thall et al. 19 reported a simulation study, for two-arm trials, comparing several Bayesian AR methods to a group sequential design using ER. 20 Their simulations showed that, compared to ER, AR methods often have a much lower probability of selecting a truly superior treatment arm, much larger estimation bias, produce distributions of N A and N B with much greater variability and skewness, and have a nontrivial probability of unbalancing N A and N B in favor of the inferior treatment. Thus, only reporting mean sample sizes from simulations may be very misleading. The particular way an AR method is defined, and other aspects of a trial design, can greatly affect the overall design performance. Because there are numerous ways to design a randomized trial, and many different ways to define AR methods, statements about the comparative desirability of AR versus ER must be accompanied by detailed explanations of these design specifics.
In this article, we report a simulation study examining four AR methods and ER in multi-arm clinical trials. A multi-arm trial design may or may not (1) include a control arm, (2) restrict the randomization to a control arm if it is included, (3) involve various rules for between-arm comparisons or stopping an arm early, (4) enrich the remaining arms with larger sample sizes when some arms are terminated early, (5) select one best or possibly several experimental treatments, and (6) include two or more than two stages, or monitor continuously. Thus, to obtain reasonable comparisons of randomization methods, the underlying designs must have qualitatively identical structures, decision rules, and maximum sample size. To obtain results that are useful to practitioners, we evaluate several relatively simple clinical trial designs and AR methods, for five-arm trials that either do or do not include a control arm. We consider Bayesian designs for trials with binary outcomes that use either ER or one of four specific AR methods.
Outcome AR methods
There are many ways to do AR. 2, 6, 7, 21, 22 The Bayesian AR methods considered here are similar to those previously studied for two-arm trials, generalized to accommodate multi-arm trials here. 1, 19, 23 Index treatments by k = 1, . . . , K, and intermediate sample sizes by n = 1, . . . , N, for maximum overall sample size N. Denoting response probabilities of the K treatments by p 1 , . . . , p K , the AR probabilities are defined in terms of the K posterior probabilities r k, n = Pr(p k = maxfp 1 , . . . , p K g j data n ), k = 1, . . . , K, ð1Þ which sum to 1. Thus, r 1, n , . . . , r K, n generalize the original definition 1 given for K = 2:
It is well known that using fr 1, n , . . . , r K, n g as AR probabilities often leads to undesirable treatment assignments due to ''stickiness,'' wherein an outcome adaptive treatment assignment rule assigns a suboptimal treatment to an undesirably large number of patients. 24 With the above AR probabilities, if a truly inferior treatment arm happens to have a higher early success rate, it is likely to receive a larger proportion of patients thereafter, and consequently, the trial design is not likely to identify a truly superior treatment. Various modifications of r k, n have been proposed to mitigate stickiness. We consider AR methods that use different combinations of three such modifications. The first is a ''burn-in'' wherein, initially, a fixed number of patients are randomized equally among the arms, with AR applied subsequently. The second replaces r k, n with
for some c.0, with c = 0:50 used very commonly. This shrinks r k, n toward .50, so the AR method is more like ER, for which c = 0 and all r (0) k, n [ 1/K. The third modification restricts e r k, n 1 À e for small e.0: If r k, n \e, then the AR probability for arm k is set equal to e, and if r k, n .1 À e, the AR probability is set equal to 1 À e, with the K resulting AR probabilities normalized so that they sum to 1. A method using r (c) k, n restricted to ½e, 1 À e will be denoted by AR(c, e):
All designs include a burn-in with the first 50 patients randomized equally among the arms, with exactly 10 patients assigned to each arm. We first consider AR(1, 0), which randomizes patients to arm k with probability r k, n , a K-arm generalization of Thompson, 1 but imposing a burn-in. The second method, AR(0:5, 0), randomizes patients to arm k with probability r (0:5) k, n given by equation (2) . AR(0:5, 0) minimizes the expected number of non-responders. 11 The third method, AR(n=2N , 0), generalizes Thall and Wathen's 23 two-arm trial method by applying equation (2) using c = n=2N , for current sample size n = 1, . . . , N : The fourth method, AR(1, 0:10), uses r k, n with the restriction 0:10 r k, n 0:90: We thus evaluate AR(1, 0), AR(0:5, 0), AR(n=2N , 0), AR(1, 0:10), and ER.
Trial designs
Each simulation case is determined by whether a control arm is included, the maximum sample size N = 250 or N = 500, decision rules, and randomization method. All cases are five-arm trials. When a control arm, C, is included, we index it by k = C and the four experimental arms by k = 1, 2, 3, 4: When C is not included, we index the five experimental treatments by k = 1, 2, 3, 4, 5: For all designs, we assume the response probabilities, fp k g, are independent with beta (0:20, 0:80:) priors. Each design requires one parameter, a U , to define the treatment arm selection rule, determined via preliminary simulations under the null scenario where all fixed response probabilities equal 0.20.
When C is included, its response probability, p C , is used as the comparator in the decision rules. These rules may stop randomization to an experimental arm E k due to futility, or select an E k as promising, based on the posterior of p k À p C : If no control arm is included, one possible approach is to use a fixed standard probability, p C , for comparison. Unless p C is completely arbitrary, this requires the assumption that there exists a standard treatment with response probability known to equal p C , that is, Pr(p C = p C ) = 1. It also requires that the numerical value p C , obtained in practice from previous trials or clinical experience, will remain a valid comparator during the trial. This implies there are no between-trial or trial-versus-historical effects. Because these are very unrealistic assumptions, we do not consider designs assuming a fixed standard. Thus, the designs without a control arm that we consider make decisions based on comparisons among the E k 's.
Multi-arm trials with a control arm
For each experimental arm, E k , k = 1, 2, 3, 4, after the initial burn-in, the following decision rules are applied continuously during the trial.
FUTILITY. For each k = 1, 2, 3, 4, arm E k is terminated early due to futility if Pr(p k .p C + 0:20 j data n )\0:01 If all four experimental arms are terminated, the trial is stopped.
ENRICHMENT. If an E k is terminated early for futility, the remaining patients, up to N, are randomized among the remaining open arms.
SELECTION. If E k is not terminated early, then at the end of the trial E k is selected if
The design thus allows more than one E k to be selected. It is typical practice to require a new treatment to provide a minimal clinically significant improvement, here specified to be d = 0:20. The futility rule decreases the number of patients randomized to an E k that is very unlikely to achieve the targeted improvement over C, and thus enriches the sample sizes of arms having larger success probabilities. For each design, the numerical value of a U is determined to ensure overall false-positive probability 0.05 for the trial, with a false positive defined as selecting any E k in the null case where all true p k = 0:20. The numerical value of a U depends on the randomization method, the value of N and the initial burn-in. Supplementary Table S1 gives the numerical value of the cut-off a U used by each design's selection rule in each case. An alternative to deriving a U in this way is to set it equal to a fixed value, such as a U = 0:95. We chose to determine a U for each design to obtain the same overall false-positive probability 0.05 in order ensure fair comparisons among the randomization methods in terms of per-arm selection probabilities, stopping probabilities, and sample size distributions.
Multi-arm trials without a control arm
For trials without a control arm, the decision rules are as follows:
ENRICHMENT. If an E k is closed early for futility, the remaining patients, up to maximum sample size N, are randomized among the remaining open arms.
SELECTION. If E k is not terminated early, at the end of the trial E k is selected if
At the end of the trial, the designs with a control arm may select more than one E k , whereas the designs without a control arm may select at most one E k : While one might question why at most one E k may be selected in trials without a control arm, it is extremely unlikely that two different p k 's both will satisfy the criterion (4) for any reasonably large a U : Moreover, in the cases of no control arm, there is no required improvement, such as the value d = 0:20 that is used in the selection rule. If the selection criterion (4) was replaced by Pr(p k .maxfp r : r 6 ¼ kg + d j data n ).a U for d = 0:15 or 0.20, our simulations show that, for N= 250 or 500 in a five-arm trial, this design would be extremely unlikely to correctly select any E k in many scenarios where there actually are substantive differences among the p k s.
Simulation study design
Under the Bayesian formulation, the probabilities, p C , p 1 , . . . , p 4 in the case with a control arm, or p 1 , . . . , p 5 in the case without a control arm, are random. We distinguish between these random quantities and corresponding assumed fixed probabilities, denoted using p k in place of p k , that are used to define scenarios and simulate data. In all simulation scenarios, we assumed fixed null response rate 0.20. We consider three scenarios. In the null scenario, all p k = 0:20. The least favorable configuration is determined, in the case with a control arm, by assuming that (1) no experimental p k is between p C and p C + d and (2) at least one experimental arm has p k ! p C + d: The least favorable configuration is the vector of p 1 , . . . , p K values that minimizes the probability, under (1) and (2) , that at least one E k for which p k ! p C + d is selected. The name ''least favorable configuration'' is somewhat misleading, since the requirements (1) and (2) are quite strong, and they ensure that it is relatively easy to identify the one E k providing a d improvement over p C : This motivates the third, more realistic ''staircase'' scenario, for which the p k 's are 0.20, 0.25, 0.30, 0.35, and 0.40.
Simulation results for trials with a control arm
In Tables 1 and 2 , n(95% CI) denotes the mean and (2.5th and 97.5th) percentiles of each per-arm sample size distribution.
In practice, an AR-based design with a large sample size imbalance favoring a superior arm is unlikely to be used if it has substantially lower probability of correctly selecting E 4 than ER. Table 2 shows that, under the least favorable configuration with p 4 = 0:40 and N = 250, AR(1,0), AR( 1 2 , 0) and AR( n 2N , 0) all have very low probability of correctly selecting E 4 , between 0.44 and 0.48, compared to AR(1, 0.1) and ER, which have probability of correct selection values 0.67 and 0.66. One reason for this large loss in probability of correct selection for AR(1,0), AR( 1 2 , 0) and AR( n 2N , 0) is that each gets stuck randomizing patients to E 4 very early in the trial, resulting in a smaller n for C. The AR methods have n ranging from 23 to 35, with the widest 95% CI (11, 70) for AR( 1 2 , 0), compared to n = 72 and 95% CI (37, 110) for ER. AR(1, 0.1) provides a favorable sample size imbalance, with n = 127 for E 4 compared to n = 70 with ER. To ensure false-positive probability 0.05, the cut-off a U in the selection rule (3) must be larger for AR(1,0), AR( 1 2 , 0) and AR( n 2N , 0) compared to AR(1, 0.1) or ER, resulting in much smaller Pr(Select E 4 ) for the first three AR methods .
Thall and Wathen 23 and Thall et al. 19 showed that, in the two-arm case, there is a significant risk that AR(1,0) and AR( 1 2 , 0) will get stuck randomizing more patients to the inferior treatment arm. To determine whether this holds in the multi-arm case, we calculate h m = Pr(N C .N k + m) for m = 10, 20, or 30 for each method. When some E k is superior, h m is the probability that a method will randomize at least m more patients to the inferior control arm than to E k : An AR procedure having h m much larger than that obtained with ER is undesirable. Under the least favorable configuration with p 4 = 0:40, using AR(1, 0.1), on average, 127 patients are treated with E 4 compared to 70 using ER, so an additional 57 patients are treated with E 4 as a result of using AR(1, 0.1), which has h 10 = 0:05 compared to 0.23 for ER. The reason that ER has larger Table 1 . Simulation results for designs with a control arm in the null scenario with all p k = 0:20, for N = 250. n = mean per-arm sample size. Each h m = Pr(N C .N k + m), the probability that the number of patients randomized to arm C is at least m larger than the number randomized to arm E k : Values in the row E 1 -E 4 are per-arm.
Method
Arm Pr(Select E 4 ) and reducing the likelihood of randomizing patients to inferior treatments. In the staircase scenario, it is much more difficult to discriminate among the E k 's. Table 3 summarizes the simulations in this case for trials including C with N = 250. Compared to ER, AR(1, 0.1) has sightly smaller probabilities of selecting E 3 or E 4 , which have p 3 = 0:35 and p 4 = 0:40: This is due to the fact that E 1 , E 2 , and E 3 remain in the trial longer because these treatments provide some improvement over C, limiting the number of patients treated with E 4 , and reducing the probability that any AR method will select E 4 : Still, AR(1, 0.1) assigns more patients to the better treatment arms, on average. Additionally, h 10 , h 20 , and h 30 each are smaller for AR(1, 0.1) compared to ER. Compared to AR(1, 0.1) or ER, the probabilities of selecting the best arms E 4 or E 5 are much smaller for AR(1,0), AR( 1 2 , 0) and AR( n 2N , 0). Tables 2 and 3 show that, for designs with a control arm and N = 250 patients, in the least favorable configuration or staircase scenarios, the highest probabilities of selecting the best arm are 0.66 or 0.67, obtained by AR(1, 0.1) or ER. A trial probably would not be conducted if there were only a 66% chance of selecting an E k achieving the targeted improvement. In practice, one would either increase N, increase the false-positive rate, or both. Supplementary Tables S1-S3 summarize the simulations in the three scenarios for N = 500 with a control arm. Table S3 shows that N = 500 gives much larger probabilities of selecting superior E k 's in the staircase scenario, with E 4 selected with probabilities 0.84 by AR(1, 0.1) and 0.86 by ER, while the other three AR methods have substantially inferior performance. Tables S2 and S3 show that, under the least favorable configuration, for N = 500, the probability of stopping superior arm E 4 is 0.08-0.09 for AR(1,0.01). If desired, these Pr(Stop) values may be made smaller by reducing the futility stopping rule cut-off to a value smaller than .01, such as .005, but the price would be smaller per-arm sample sizes for E 4 and consequently lower Pr(Select) values. Table 4 compares Pr(Select E 4 ) for N = 250 and N = 500 under the least favorable configuration when p 4 = 0:40. When N = 500, AR(1, 0.1) and ER have Pr(Select E 4 ) values 0.87 and 0.85. Compared to ER, although AR(1, 0.1) has a much more disperse subsample size distribution for E 4 , on average AR(1, 0.1) randomizes many more patients to E 4 . The Pr(Select E 4 ) values 0.77, 0.67, and 0.53 for AR( n 2N , 0), AR( 1 2 , 0), and AR(1,0) are much smaller. AR( 1 2 , 0)would require Table 5 . Simulation results for designs without a control arm in the null scenario p 1 = Á Á Á = p 5 = 0:20, for N = 250. Each h m = Pr(N E1 .N Ek + m), the probability that the number of patients randomized to arm C is at least m larger than the number randomized to arm E k : All values are per-arm. 

Simulation results for trials without a control arm
Each design without a control arm was calibrated to have a 1% chance of selecting each treatment in the null scenario (Table 5 ). In the least favorable configuration scenario with p 5 = 0:40 and N = 250, Table 6 shows that all methods provide Pr(Select E 4 ) for E 4 ranging from 0.75 to 0.82, and all of the h m values are relatively small for E 4 . If the only cases considered were the null and the least favorable configuration, then it might seem that running a multi-arm trial including a control arm is foolish. However, the opposite is true. Table 7 shows that, in the staircase scenario, for N = 250, the probabilities of selecting the best treatments are extremely low, ranging from 0.19 to 0.26, compared to approximately 0.65 when a control arm is included. The main reason for this large drop is that, without a control arm, comparison among the E k 's is extremely difficult if the differences between the p k s are small. Supplementary Table S6 shows that, in the staircase scenario, even if the overall maximum sample size is increased to N = 500, the selection probabilities for E 5 range from 0.33 to 0.39 for any randomization method, with selection probabilities at most 0.04 for any of E 1 , . . . , E 4 :
Discussion
A general conclusion is that, for multi-arm trials, AR(1, 0), AR( 1 2 , 0), and AR( n 2N , 0) should not be used. If one wishes to use some AR method in a multi-arm trial, if an initial burn-in is imposed, the superior performance of AR(1, 0.1) indicates that it is important to restrict the domain of possible AR probabilities by bounding them away from 0 and 1. Given the apparent popularity of AR(1,0) and AR(0.50, 0), this is a very important result. While we have not examined other hybrid methods, such as AR(.50, .10) or AR(n/2N, .10), the simulations suggest that these may perform well compared to AR(1, .10) or ER. The numerical limit e cannot be arbitrary, since, for example, AR(0.50, 0.20) would be close to ER in a five-arm trial. ER does the best job of selecting treatments having p k 's that are superior but close to each other.
In practice, it is not unlikely that two or more p k 's may be close to each other, so the staircase scenario may be closer to reality than the least favorable configuration. When the p k 's are close to each other, it is very difficult to select any E k if no C is included as a comparator. The simulations in the staircase scenario indicate that conducting a multi-arm trial without a control arm may be a waste of resources, for any randomization method, and it is best to include a control arm in a multi-arm selection trial.
Many elaborations and alternative cases are possible, including time-to-event or multivariate outcomes, accounting for covariates, and evaluating AR methods for multi-arm trials in the presence of drift. This latter issue is closely related to so-called platform designs, which allow experimental arms to enter a trial after it has started. 25 These are important areas for future simulation study. Table 6 . Simulation results for designs with no control arm in the least favorable configuration scenario p 1 = p 2 = p 3 = p 4 = 0:20 and p 5 = 0:40, for N = 250. n = mean per-arm sample size. Each h m = Pr(N E1 .N Ek + m), the probability that the number of patients randomized to arm E 1 is at least m larger than the number randomized to arm E k : Values in the row E 1 À E 4 are per-arm.
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Arm Table 7 . Simulation results for designs with no control arm in the staircase scenario, (p 1 , p 2 , p 3 , p 4 , p 5 ) = (0:20, 0:25, 0:30, 0:35, 0:40), for N = 250. n = mean per-arm sample size. h m = Pr(N E1 .N Ej + m), the probability that the number of patients randomized to E 1 is at least m larger than the number randomized to E j : 
